姓名：张琪

职称：教授，硕士生导师

学术兼职：

江苏省高校医药教育研究会 副理事长；

江苏省药理学会 常务理事；

《中国临床药理学与治疗学》、《中华男科学杂志》编委

教育简历：

中国药科大学 药理学博士；

美国纽约州立大学布法罗分校（State University of New York at Buffalo）博士后。

研究领域：药理学、药物动力学、代谢组学。

在基础研究领域着重于各类新药的临床前与临床的药物动力学、药效学筛选、药理学机制靶点、药效-药动学模型研究，以及骨质疏松症、高脂血症等重大疾病的代谢组学研究。尤其是代谢组学方法学及其应用的研究成果处于国内外前列。

主持了碱性成纤维细胞生长因子、黄芪甲苷、磷酸二果糖锶等一类新药的药理学、药动学研究及Etanercept、银杏提取物、硝苯地平缓释片、阿司匹林缓释片等四十多种新药的药理学、药物动力学、生物等效性研究及相关的新药报批，推动企业新药成果的市场转化。

近年来负责国家自然科学基金三项（主持两项：“二磷酸果糖锶防治男性性功能低下：对雄性素生成等相关基因的调控”、“二磷酸果糖锶盐对抗ET-ROS介导的雄性性功能低下与睾丸退行性病变”；联合单位负责人一项“miR-30a介导炎症信号的异常转归影响精子成熟的机制研究”）；国际合作项目一项（PK/PD/PG/DIS Models for Etanercept Interactions with Cytokines in a Rat Model of RA）；省基金一项（抗骨质疏松一类新药的临床前研究）；参与国家、省部科研项目8项；主持企业合作项目40多项。申请专利3项（2项授权）。发表学术文章61篇（30篇被SCI收录）；参与编写英文论著一部、中文著作多部。

所获荣誉：

江苏省“333高层次人才培养工程”培养对象

江苏省“六大人才高峰”培养对象

南京市“321”领军型科技创业人才

南京工业大学首届“工大才俊”高层次人才培养对象

讲授课程：

药理学、药物动力学（本科生课程）；现代药理学（研究生课程）

科研成果：

参与编写的中英文论著：

英文论著：《Strontium: Chemical Properties, Applications and Health Effects》一书中的第一章节 “The Effects of Strontium on Physiology, Pharmacology and Toxicity of the Human”

出版社：NOVA Publishers  出版日期：2013年  ISBN：978-1-62257-631-9

中文论著：《10000个科学难题（医学卷）》， “药动学-药效学结合模型—连接体内药物浓度与药效关系的桥梁”，科学出版社，2011年8月正式出版，P955-958。 “十一五”国家重点图书出版规划项目

近年发表的SCI文章：

[1] Metabolomic Profiles Delineate Signature Metabolic Shifts during Estrogen Deficiency-Induced Bone Loss in Rat by GC-TOF/MS. PLOS ONE, 2013,8(2):e54965.

[2]   Simultaneous determination of Eleutheroside B and Eleutheroside E in rat plasma by high performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B AnalytTechnol Biomed Life Sci, 2013,917-918:84-92.

[3] Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal, 2013,77C:149-157.

[4] Simultaneous Determination of Oridonin, Ponicidin and Rosmarinic Acid from Herba  IsodiRubescentis Extract by LC-MS-MS in Rat Plasma. J ChromatogrSci, 2013.

[5] Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of raddeanin A in rat plasma and its application to a pharmacokinetic study. J Chromatogr B AnalytTechnol Biomed Life Sci, 2013,912:16-23.

[6] Strontium fructose 1, 6-fiphosphate (FDP-Sr) treatment prevents bone loss in a rat model of postmenopausal osteoporosis via OPG\RANKL\RANK pathway. ActaPharmacologicaSinica, 2012, 33(4): 479-489 IF: 1.95

[7] Simultaneous determination of oridonin, ponicidin and rosmarinic acid from HerbaIsodiRubescentis extract by LC-MS/MS in rat plasma. Journal of Chromatographic Science 2012

[8] Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of raddeanin A in rat plasma and its application to a pharmacokinetic study. Journal of Chromatography B，2013（912）:16-23

[9] Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction  against upregulatedcavernosal NADPH oxidase, protein kinase Cε, and endothelin system in diabetic rats. J Pharm Pharmacol. 2012 Feb;64(2):244-51.

[10] GC-TOF/MS-based metabolomicproiling of estrogen deiciency-induced obesity in ovariectomized rats. ActaPharmacologicaSinica  2011(32): 270-278

[11] Synthesis and pharmacokinetics of strontium fructose 1,6-diphosphate (Sr-FDP) as a potential anti-osteoporosis agent in intact and ovariectomized rats. J InorgBiochem, 2011,105(4):563-568.

[12] Determination of strontium in rat plasma and plasma ultrafiltrate by Zeeman Furnace atomic absorption spectroscopy and its application to a pharmacokinetic study. African Journal of Biotechnology 2011.10(78), 18039-18045

[13] Pharmacokinetic—Pharmacodynamic—Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis, Pharm Res. 2011（28）: 1622-1630 

[14] Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats. ActaPharmacologicaSinica, 2011, 32: 441-448. I

[15] Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. Journal of Pharmacy and Pharmacology, 2011, 63: 943-951.

[16] Metabonomic profiling of diet-induced hyperlipidaemia in a rat model. Biomarkers 2010 May;15(3):205-16.

[17] Upregulated NADPH Oxidase Contributes to Diabetic Testicular Complication and is Relieved by Strontium Fructose 1,6-Diphosphate. ExpClinEndocrinol Diabetes 2010; 118: 459–465.

[18] Strontium fructose 1,6- diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metallop- roteinase system in streptozocin-treated rats [J]. J Pharmacy Pharmacology, 2009, 61: 229-236  

[19] (2-Pyridyl)acetone-Promoted Cu-Catalyzed O- Arylation of Phenols with Aryl Iodides, Bromides, and Chlorides. The Journal of Organic Chemistry, 2009, 74:7187–7190

[20] Application of GC/MS-based metabonomic profiling in studying the lipid-regulating effects of Ginkgo biloba extract on diet-induced hyperlipidemia in rats. ActaPharmacologicaSinica, 2009, 30(12):1674-1687

[21] Effects of strontium fructose 1,6-diphosphate on expression of apoptosis-related genes and oxidative stress in testes of diabetic rats [J]. International Journal of Urology (2008) 15, 251–256 

[22] A new chromone glycoside from  Rhododendron  spinuliferum. Archives of Pharmacal Research  (2008), 31(8),970-972.

[23] GC/MS analysis of the rat urine for metabonomic research [J]. Journal of Chromatography B 2007,854(2), 20-25.  

[24] Pharmacokinetics of astragaloside Ⅳ in beagle dogs [J]. European Journal of Drug Metabolism and Pharmacokinetics 2007, 32(2), 75-9.

[25] Strontium Fructose 1,6-diphosphate Rescues adenine-induced Male Hypogonadism and Upregulates the Testicular Endothelin-1 System [J].Clinical and Experimental Pharmacology and Physiology 2007,34:1131-1137. 

[26] Pharmacokinetics of Astragaloside IV in Rats by liquid hromatography coupled with tandem mas spectrometry [J]. European Journal of Drug Metabolism and Pharmacokinetics 2005, 30(4), 269-273. 

[27] Pharmacokinetics of Recombinant Human Basic Fibroblast Growth Factor in Mice using a Radioiodionati- on method combined with SDS-PAGE and a Sandwich Enzyme-Linked Immunosorbent Assay [J]. European Journal of Drug Metabolism and Pharmacokinetics 2004, 29(3), 163-168 

[28]. Pharmacokinetics of recombinant human basic fibroblast growth factor in rabbits and mice serum and rabbits aqueous humor [J]. ActaPharmacol Sin, 2004 Aug; 25(8):991-995.